Evelo Biosciences
Biotechnology, 620 Memorial Dr, Cambridge, Massachusetts, United States, 51-200 Employees
Phone Number: 61********
Who is EVELO BIOSCIENCES
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAXTM, with systemic t...
Read More
-
Headquarters: 620 Memorial Dr, Cambridge, Massachusetts, United States
-
Date Founded: 2015
-
Employees: 51-200
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from EVELO BIOSCIENCES
Evelo Biosciences Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Evelo Biosciences
Answer: Evelo Biosciences's headquarters are located at 620 Memorial Dr, Cambridge, Massachusetts, United States
Answer: Evelo Biosciences's phone number is 61********
Answer: Evelo Biosciences's official website is https://evelobio.com
Answer: Evelo Biosciences's revenue is $50 Million to $100 Million
Answer: Evelo Biosciences's SIC: 2834
Answer: Evelo Biosciences has 51-200 employees
Answer: Evelo Biosciences is in Biotechnology
Answer: Evelo Biosciences contact info: Phone number: 61******** Website: https://evelobio.com
Answer: Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAXTM, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Companys first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelos therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer. Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month